BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 26494300)

  • 1. Bone stroma-derived cells change coregulators recruitment to androgen receptor and decrease cell proliferation in androgen-sensitive and castration-resistant prostate cancer cells.
    Villagran MA; Gutierrez-Castro FA; Pantoja DF; Alarcon JC; Fariña MA; Amigo RF; Muñoz-Godoy NA; Pinilla MG; Peña EA; Gonzalez-Chavarria I; Toledo JR; Rivas CI; Vera JC; McNerney EM; Onate SA
    Biochem Biophys Res Commun; 2015 Nov; 467(4):1039-45. PubMed ID: 26494300
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Altered corepressor SMRT expression and recruitment to target genes as a mechanism that change the response to androgens in prostate cancer progression.
    Godoy AS; Sotomayor PC; Villagran M; Yacoub R; Montecinos VP; McNerney EM; Moser M; Foster BA; Onate SA
    Biochem Biophys Res Commun; 2012 Jul; 423(3):564-70. PubMed ID: 22695118
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Androgens modulate expression of transcription intermediary factor 2, an androgen receptor coactivator whose expression level correlates with early biochemical recurrence in prostate cancer.
    Agoulnik IU; Vaid A; Nakka M; Alvarado M; Bingman WE; Erdem H; Frolov A; Smith CL; Ayala GE; Ittmann MM; Weigel NL
    Cancer Res; 2006 Nov; 66(21):10594-602. PubMed ID: 17079484
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Androgen receptor stabilization in recurrent prostate cancer is associated with hypersensitivity to low androgen.
    Gregory CW; Johnson RT; Mohler JL; French FS; Wilson EM
    Cancer Res; 2001 Apr; 61(7):2892-8. PubMed ID: 11306464
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Androgen receptors in hormone-dependent and castration-resistant prostate cancer.
    Shafi AA; Yen AE; Weigel NL
    Pharmacol Ther; 2013 Dec; 140(3):223-38. PubMed ID: 23859952
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CH5137291, an androgen receptor nuclear translocation-inhibiting compound, inhibits the growth of castration-resistant prostate cancer cells.
    Ishikura N; Kawata H; Nishimoto A; Nakamura R; Tsunenari T; Watanabe M; Tachibana K; Shiraishi T; Yoshino H; Honma A; Emura T; Ohta M; Nakagawa T; Houjo T; Corey E; Vessella RL; Aoki Y; Sato H
    Int J Oncol; 2015 Apr; 46(4):1560-72. PubMed ID: 25634071
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Androgen ablation elicits PP1-dependence for AR stabilization and transactivation in prostate cancer.
    Liu X; Han W; Gulla S; Simon NI; Gao Y; Liu J; Wang L; Yang H; Zhang X; Chen S
    Prostate; 2016 May; 76(7):649-61. PubMed ID: 26847655
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Androgen Receptor Coactivators in Regulation of Growth and Differentiation in Prostate Cancer.
    Culig Z
    J Cell Physiol; 2016 Feb; 231(2):270-4. PubMed ID: 26201947
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification of an anabolic selective androgen receptor modulator that actively induces death of androgen-independent prostate cancer cells.
    Schmidt A; Meissner RS; Gentile MA; Chisamore MJ; Opas EE; Scafonas A; Cusick TE; Gambone C; Pennypacker B; Hodor P; Perkins JJ; Bai C; Ferraro D; Bettoun DJ; Wilkinson HA; Alves SE; Flores O; Ray WJ
    J Steroid Biochem Mol Biol; 2014 Sep; 143():29-39. PubMed ID: 24565564
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Androgens induce a distinct response of epithelial-mesenchymal transition factors in human prostate cancer cells.
    Colditz J; Rupf B; Maiwald C; Baniahmad A
    Mol Cell Biochem; 2016 Oct; 421(1-2):139-47. PubMed ID: 27562825
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Activity of androgen receptor antagonist bicalutamide in prostate cancer cells is independent of NCoR and SMRT corepressors.
    Hodgson MC; Astapova I; Hollenberg AN; Balk SP
    Cancer Res; 2007 Sep; 67(17):8388-95. PubMed ID: 17804755
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cell-line and tissue-specific signatures of androgen receptor-coregulator transcription.
    Bebermeier JH; Brooks JD; DePrimo SE; Werner R; Deppe U; Demeter J; Hiort O; Holterhus PM
    J Mol Med (Berl); 2006 Nov; 84(11):919-31. PubMed ID: 16932916
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Steroidogenic enzyme AKR1C3 is a novel androgen receptor-selective coactivator that promotes prostate cancer growth.
    Yepuru M; Wu Z; Kulkarni A; Yin F; Barrett CM; Kim J; Steiner MS; Miller DD; Dalton JT; Narayanan R
    Clin Cancer Res; 2013 Oct; 19(20):5613-25. PubMed ID: 23995860
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Testosterone boosts for treatment of castration resistant prostate cancer: an experimental implementation of intermittent androgen deprivation.
    Thelen P; Heinrich E; Bremmer F; Trojan L; Strauss A
    Prostate; 2013 Nov; 73(15):1699-709. PubMed ID: 23868789
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Stromal-epithelial cell interactions and androgen receptor-coregulator recruitment is altered in the tissue microenvironment of prostate cancer.
    Cano P; Godoy A; Escamilla R; Dhir R; Onate SA
    Cancer Res; 2007 Jan; 67(2):511-9. PubMed ID: 17234758
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of MAPK-signaling pathway promotes the interaction of the corepressor SMRT with the human androgen receptor and mediates repression of prostate cancer cell growth in the presence of antiandrogens.
    Eisold M; Asim M; Eskelinen H; Linke T; Baniahmad A
    J Mol Endocrinol; 2009 May; 42(5):429-35. PubMed ID: 19223455
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prostate cancer cells increase androgen sensitivity by increase in nuclear androgen receptor and androgen receptor coactivators; a possible mechanism of hormone-resistance of prostate cancer cells.
    Fujimoto N; Miyamoto H; Mizokami A; Harada S; Nomura M; Ueta Y; Sasaguri T; Matsumoto T
    Cancer Invest; 2007 Feb; 25(1):32-7. PubMed ID: 17364555
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Resveratrol inhibits hypoxia-inducible factor-1α-mediated androgen receptor signaling and represses tumor progression in castration-resistant prostate cancer.
    Mitani T; Harada N; Tanimori S; Nakano Y; Inui H; Yamaji R
    J Nutr Sci Vitaminol (Tokyo); 2014; 60(4):276-82. PubMed ID: 25297617
    [TBL] [Abstract][Full Text] [Related]  

  • 19. c-Jun enhancement of androgen receptor transactivation is associated with prostate cancer cell proliferation.
    Chen SY; Cai C; Fisher CJ; Zheng Z; Omwancha J; Hsieh CL; Shemshedini L
    Oncogene; 2006 Nov; 25(54):7212-23. PubMed ID: 16732317
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A hnRNP K⁻AR-Related Signature Reflects Progression toward Castration-Resistant Prostate Cancer.
    Capaia M; Granata I; Guarracino M; Petretto A; Inglese E; Cattrini C; Ferrari N; Boccardo F; Barboro P
    Int J Mol Sci; 2018 Jun; 19(7):. PubMed ID: 29966326
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.